|
|
Matt Sullivan$0.021/22/08 $999,371.80 |
No Analyses 05/11/09 0% -0.1% |
|
| Since Start | Nov | Oct | Sep | Aug | Jul | Jun | May | |
|---|---|---|---|---|---|---|---|---|
| mattsulliv- | -0.1% | 0% | 0% | 0% | 0% | 0% | 0% | -0.1% |
| S&P 500 | 17.4% | 5.3% | -2% | 3.6% | 3.4% | 7.4% | 0% | 5.3% |
| Name | Size | Avg. Return | Avg. November | Top Players |
|---|---|---|---|---|
| The Ohio State University | 296 | 6.0% | 2.0% |
|
| Member | Since Start [Annualized] |
Today | This Month | Analysis | |
|---|---|---|---|---|---|
| -0% | 0.1% | -3.6% | 2 |
|
| Contest | Players | Leaders | Rank | ||||||
|---|---|---|---|---|---|---|---|---|---|
$5,000 Official UpDown 2009 Performance Contest |
49,206 |
|
43789 out of 49206
|
||||||
|
November 2009 $3,000 Monthly Performance Contest |
9,190 |
|
-- out of 9190
|
|
|
Matt Sullivan |
May 10 6:23 PM |
|
Dendreon sounds like a sure thing with the FDA's approval, however insiders dumped a bunch of stock on Friday...makes me suspicious. - DNDN
Comment |
||
Matt Sullivan has not added expertise